Who is the CEO of Hyundai Bioscience?

According to the DART company overview, Hyundai Bioscience's representative director is 진근우 (name as registered in Korean). The company was founded on 2000-05-25.

Where is Hyundai Bioscience listed?

Hyundai Bioscience trades on the Korea Exchange KOSDAQ market under the ticker 048410. Its fiscal year ends in December.

Does Hyundai Bioscience pay a dividend?

Hyundai Bioscience did not pay a cash dividend for fiscal 2025, according to its annual report.

Does Hyundai Bioscience have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: 4 quarters of losses (operating loss in each of the last four quarters); Insider selling (officers or major shareholders reported cutting shares (30 days)). 1 more signal is shown on the page. These are factual flags, not investment advice.

Which companies are in the same industry as Hyundai Bioscience?

Under the Korean Standard Industrial Classification recorded on DART, Hyundai Bioscience is grouped with 99 other listed companies in specialty chemicals. The most covered in Korean news over the past 30 days are Amorepacific, Apr and LG H&H.

Hyundai Bioscience KRX:048410KOSDAQ

현대바이오 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h8

Articles, 7 days25

DART filings, 7 days2

Articles tracked25since Sep 11

In Q2 2026, Hyundai Bioscience reported revenue of ₩520m, up 56.3% year on year, and an operating loss of ₩5.5bn. Hyundai Bioscience (현대바이오) appeared in 25 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Oct 13 with 25 articles. The most common catalyst was clinical & approvals (17).

Filing signals 4 quarters of losses Insider selling Share pledge Screener

Hyundai Bioscience quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩520m	+56.3%	−₩5.5bn	−₩11.6bn
Q1 2026	₩325m	-54.2%	−₩4.7bn	−₩5.3bn
Q4 2025 derived	₩1.9bn	+426.0%	−₩4.4bn margin −230.9%	−₩4.7bn
Q3 2025	₩553m	+20.6%	−₩4.6bn	−₩7.0bn
Q2 2025	₩333m	-96.4%	−₩4.8bn	−₩4.3bn
Q1 2025	₩709m	-86.0%	−₩4.3bn	−₩6.1bn
Q4 2024 derived	₩366m	-67.8%	−₩2.8bn	−₩4.6bn
Q3 2024	₩459m	-76.6%	−₩3.3bn	−₩5.1bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Hyundai Bioscience top stories 2 weeks, by number of outlets

1
현대바이오 "SFTS 치료제 개발 추진…임상 2상 신속 진입"
7 outlets · 9 articlesFirst report Oct 13 11:00 연합뉴스경제Clinical trial
2
현대바이오, 치료제 없는 '살인진드기병' 공략한다…임상 2상 준비
2 outlets · 2 articlesFirst report Oct 13 11:16 뉴스1Clinical trial
3
[바이오현장] 치명률 18%인데 치료제 '0'…현대바이오, '살인진드기병'에 정면 도전
2 outlets · 2 articlesFirst report Oct 13 15:40 EBN
4
현대바이오 "제프티 SFTS 임상 2상 추진"…비임상 근거 활용
1 outlets · 1 articlesFirst report Oct 13 12:21 메디파나뉴스Clinical trial
5
[현장] 현대바이오 '살인진드기병' 치료제 임상 2상 추진..."치료 공백 해소"
1 outlets · 1 articlesFirst report Oct 13 13:50 포쓰저널Clinical trial
6
현대바이오, '살인진드기병' 치료제 임상2상 추진…"환자 모집이 관건"
1 outlets · 1 articlesFirst report Oct 13 14:40 한국경제Clinical trial

Latest Hyundai Bioscience news Korean headlines

Oct 1316:33

Major[이슈] 현대바이오, SFTS 치료 공백 깬다...'제프티' 임상 2상 IND 연내 추진
팍스경제TVClinical trial
Oct 1316:30

[현대바이오 NEXT③]제프티, SFTS 개발 근거 축적…코로나 경험 활용
PRESS9
Oct 1316:10

[현대바이오 NEXT②]치명률 18% 감염병 도전, "자국민 보호 최우선"
PRESS9
Oct 1315:50

[현대바이오 NEXT①]제프티 SFTS 임상 추진, HPV도 개발 검토
PRESS9
Oct 1315:40
[바이오현장] 치명률 18%인데 치료제 '0'…현대바이오, '살인진드기병'에 정면 도전
EBN
1 more on this story · 1 outlets
- 치명률 18% ‘살인진드기병’⋯현대바이오, 제프티로 치료제 개발 도전코메디닷컴 · Oct 13 16:46
Oct 1315:37

Major현대바이오, 제프티로 ‘살인 진드기병’ 잡는다…임상 2상 진입 추진
디지털타임스Clinical trial
Oct 1315:18

Major사망자 41명 '살인 진드기' 공포…현대바이오, 임상 2상 출사표
한국경제Clinical trial
Oct 1315:03

[현장] 현대바이오, SFTS 잡을 '제프티' 박차..."당국, 환자 확보 도와달라"
파이낸셜포스트
Oct 1314:40

Major현대바이오, '살인진드기병' 치료제 임상2상 추진…"환자 모집이 관건"
한국경제Clinical trial
Oct 1314:14

[현장] 현대바이오, 치료제 없는 SFTS 도전…내년 5월 투약 목표
한스경제
Oct 1313:50

Major[현장] 현대바이오 '살인진드기병' 치료제 임상 2상 추진..."치료 공백 해소"
포쓰저널Clinical trial
Oct 1312:21

Major현대바이오 "제프티 SFTS 임상 2상 추진"…비임상 근거 활용
메디파나뉴스Clinical trial
Oct 1311:27

치명률 18% ‘살인진드기병’ 정조준…현대바이오, ‘제프티’ SFTS 국내 2상 직행 승부수
이데일리
Oct 1311:16
Major현대바이오, 치료제 없는 '살인진드기병' 공략한다…임상 2상 준비
뉴스1Clinical trial
1 more on this story · 1 outlets
- 현대바이오, '살인진드기병' 치료제 도전…제프티 임상 2상 추진아시아투데이 · Oct 13 15:37
Oct 1311:00
Major현대바이오 "SFTS 치료제 개발 추진…임상 2상 신속 진입"
연합뉴스경제Clinical trial
8 more on this story · 7 outlets
- 현대바이오 "SFTS 치료제 개발 추진…임상 2상 신속 진입"한민족센터 · Oct 13 11:27
- 현대바이오 “치료제 없던 SFTS 치료제 개발 추진…임상 2상 신속 진입”문화일보 · Oct 13 13:36
- 현대바이오, SFTS 치료제 개발 도전…"임상 2상 신속 진입"(종합)연합뉴스경제 · Oct 13 13:50
- 현대바이오, SFTS 치료제 개발 추진…임상 2상 신속 진입스페셜타임스 · Oct 13 13:53
- 현대바이오, SFTS 치료제 개발 도전…"임상 2상 신속 진입"(종합)한민족센터 · Oct 13 13:55
- '살인 진드기' 잡는다...현대바이오 "SFTS 치료제 임상 2상 신속 진입"생생비즈플러스 · Oct 13 16:23
- 현대바이오, SFTS 치료제 개발 추진…내년 5월 임상 2상 개시 목표동아일보 · Oct 13 16:35
- SFTS 치료제 개발 나선 현대바이오…'제프티' 임상 2상 추진메디컬투데이 · Oct 13 19:33

Articles per day 2 weeks

2513

Company profile

CEO: 진근우
Industry: Specialty chemicals
Founded: 2000-05-25
Fiscal year-end: December
Head office: 경상북도 김천시
Website: hyundaibioscience.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Hyundai Bioscience in the market close daily wrap

All wraps

Shinhan's Lotte Non-Life Deal, Samsung AI Push Lead Korea NewsTue, Oct 13

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

씨앤팜11.79%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Specialty chemicals

All in industry

Company	Latest quarter op. profit	Articles 30d
Amorepacific	₩117bn	237
Apr	₩191bn	174
LG H&H	₩103bn	168
Cosmax	₩73.7bn	166
Hanwha	₩2.41tn	154
KCC	₩129bn	123
Kolmar Korea	₩110bn	87
Aekyung Industrial	₩4.5bn	82

Compare Hyundai Bioscience side by side with these companies

Hyundai Bioscience DART filings

Oct 1315:35

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Oct 1315:34

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Oct 217:23

Other [기재정정]반기보고서 (2026.06)
Other
Sep 3015:39

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Sep 1615:53

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Sep 1615:46

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports

Catalysts 2 weeks

Clinical & approvals17

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Hyundai Bioscience FAQ

Who is the CEO of Hyundai Bioscience?: According to the DART company overview, Hyundai Bioscience's representative director is 진근우 (name as registered in Korean). The company was founded on 2000-05-25.
Where is Hyundai Bioscience listed?: Hyundai Bioscience trades on the Korea Exchange KOSDAQ market under the ticker 048410. Its fiscal year ends in December.
What were Hyundai Bioscience's latest quarterly results?: In Q2 2026, Hyundai Bioscience reported revenue of ₩520m, up 56.3% year on year, and an operating loss of ₩5.5bn. Figures come from reports filed on DART.
Does Hyundai Bioscience pay a dividend?: Hyundai Bioscience did not pay a cash dividend for fiscal 2025, according to its annual report.
Does Hyundai Bioscience have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: 4 quarters of losses (operating loss in each of the last four quarters); Insider selling (officers or major shareholders reported cutting shares (30 days)). 1 more signal is shown on the page. These are factual flags, not investment advice.
Which companies are in the same industry as Hyundai Bioscience?: Under the Korean Standard Industrial Classification recorded on DART, Hyundai Bioscience is grouped with 99 other listed companies in specialty chemicals. The most covered in Korean news over the past 30 days are Amorepacific, Apr and LG H&H.